fbpx

Exerpts from the publication

Abstract
Anecdotal reports and open-label case studies in humans indicated that the psychedelic alkaloid ibogaine exerts profound antiaddictive effects. Ample preclinical evidence demonstrated the efficacy of ibogaine, and its main metabolite, noribogaine, in substance-use-disorder rodent models. In contrast to addiction research, depression-relevant effects of ibogaine or noribogaine in rodents have not been previously examined. We have recently reported that the acute ibogaine administration induced a long-term increase of brain-derived neurotrophic factor mRNA levels in the rat prefrontal cortex, which led us to hypothesize that ibogaine may elicit antidepressant-like effects in rats. Accordingly, we characterized behavioral effects (dose- and time-dependence) induced by the acute ibogaine and noribogaine administration in rats using the forced swim test (FST, 20 and 40 mg/kg i.p., single injection for each dose). We also examined the correlation between plasma and brain concentrations of ibogaine and noribogaine and the elicited behavioral response. We found that ibogaine and noribogaine induced a dose- and time-dependent antidepressant-like effect without significant changes of animal locomotor activity. Noribogaine's FST effect was short-lived (30 min) and correlated with high brain concentrations (estimated >8 μM of free drug), while the ibogaine's antidepressant-like effect was significant at 3 h. At this time point, both ibogaine and noribogaine were present in rat brain at concentrations that cannot produce the same behavioral outcome on their own (ibogaine ∼0.5 μM, noribogaine ∼2.5 μM). Our data suggests a polypharmacological mechanism underpinning the antidepressant-like effects of ibogaine and noribogaine.

Read more

Efficacy of Intravenous Ketamine in Adolescent Treatment-Resistant Depression: A Randomized Midazolam-Controlled Trial

Jennifer B Dwyer, Angeli Landeros-Weisenberger, Jessica A Johnson, Amalia Londono Tobon, José M Flores, Madeeha Nasir, Kevin Couloures, Gerard Sanacora, Michael H Bloch
April 2021

The potential synergistic effects between psychedelic administration and nature contact for the improvement of mental health

Sam Gandy, Matthias Forstmann, Robin Lester Carhart-Harris, Christopher Timmermann, David Luke, Rosalind Watts
December 2020

Rapid resolution of suicidal ideation after a single infusion of an N-methyl-D-aspartate antagonist in patients with treatment-resistant major depressive disorder

Nancy DiazGranados, Lobna A Ibrahim, Nancy E Brutsche, Rezvan Ameli, Ioline D Henter, David A Luckenbaugh, Rodrigo Machado-Vieira, Carlos A Zarate Jr
July 2010

A Single Ketamine Infusion Combined With Motivational Enhancement Therapy for Alcohol Use Disorder: A Randomized Midazolam-Controlled Pilot Trial

Elias Dakwar, Frances Levin, Carl L Hart, Cale Basaraba, Jean Choi, Martina Pavlicova, Edward V Nunes
February 2020

Details